Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Recurrent Neuroblastoma Clinical Trial

Official title:

Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02173093
• Other study ID #: 19031
• Secondary ID: NCI-2014-0114920
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 2014
• Est. completion date: December 2019

Study information

• Verified date: January 2019
• Source: University of Virginia
• Contact: Holly Davis
• Email: haw5d[@]virginia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous research has demonstrated that investigators can coat (arm) T cells with a special molecule called GD2 bispecific antibody that will help T cells recognize neuroblastoma and osteosarcoma cells and kill them. This bispecific antibody recognizes GD2, a protein found on almost all neuroblastoma and osteosarcoma cells. The investigators put the GD2 bispecific antibody on T cells and give large numbers of these T cells back to patients. The investigators think that these T cells may have a better chance of killing GD2 expressing tumor cells when they are armed with GD2 bispecific antibody. This trial studies the side effects and best dose of activated T cells armed with GD2 bispecific antibody and how well they work in treating patients with neuroblastoma, osteosarcoma, and other GD2-positive solid tumors.

Description:

PRIMARY OBJECTIVES:

I. To perform a phase I dose-escalation study in patients with recurrent or refractory neuroblastoma (NB) and other GD2-positive tumors to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) for anti-CD3 x hu3F8 bispecific antibody (GD2Bi)-armed activated T cells (aATC) infused twice a week for a total of eight infusions in combination with daily IL-2 (300,000 IU/m^2/day) and GM-CSF (250 ug/m^2 twice per week) in a standard 3 + 3 dose escalation schema with 40, 80, and 160 x 10^6 cells/kg/infusion dose levels.

II. To conduct a phase II clinical trial to explore efficacy and confirm the toxicity profile of GD2Bi-aATC combined with IL-2 and GM-CSF in a phase II expansion cohort of 22 patients with neuroblastoma (NB) using MTD determined in the phase I.

SECONDARY OBJECTIVES:

I. Evaluate immune responses in the phase I/II trial by sequential monitoring of anti-NB cytotoxicity of peripheral blood lymphocytes and IFN-gamma EliSpots directed at NB lines.

II. To evaluate persistence of aATC in the blood and tumor biopsies by staining for murine IgG2a to confirm trafficking of armed T cells to tumor.

III. To conduct exploratory study of (18F FDG) positron emission tomography (PET)/computed tomography (CT) after armed ATC infusions in selected patients with PET/CT measurable soft tissue and skeletal lesions.

OUTLINE: This is a phase I, dose-escalation study of OKT3/humanized 3F8 bispecific antibody-aATC followed by a phase II study.

Patients receive IL-2 subcutaneously (SC) daily on days -2 to 35, sargramostim SC twice weekly for 4 weeks, and OKT3/humanized 3F8 bispecific antibody-aATC intravenously (IV) over 30 minutes twice weekly for 4 weeks.

After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Months to 29 Years

Eligibility

The study is now in the phase II expansion phase.

Inclusion Criteria for phase II:

• The target tumor is limited to neuroblastoma and the diagnosis should be histologically verified.

• Patients must have refractory or recurrent malignancy; patient's current disease state must be one for which no known curative therapy is available;

• Patients should not receive any other experimental or phase 1 therapy within 3 weeks prior to study enrollment and monoclonal antibody therapy within 6 weeks

• To be eligible for phase I study patients should have primary refractory or relapsed disease as evidenced by:

• Local tumor recurrence measurable on CT or magnetic resonance imaging (MRI) scans with or without metastatic lesions

• Refractory bone marrow involvement in patients with NB

• NB with MIBG-positive skeletal lesions

• The presence of radiographically measurable disease immediately prior to start of Phase I immunotherapy is not an eligibility requirement in the following situations:

• In patients with NB who have documented bone marrow (BM) involvement;

• In patients with NB who have MIBG-positive bony lesion(s);

• An additional eligibility requirement for phase II study includes the presence of radiographically measurable disease with the exception of MIBG-positive NB or NB with bone marrow involvement:

• Patients must have a Lansky or Karnofsky performance status score of >= 70

• Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy

• Myelosuppressive chemotherapy: must not have received within 3 weeks of starting immunotherapy (IT)

• Hematopoietic growth factors: at least 7 days since the last dose of growth factor therapy

• Immunotherapy: at least 6 weeks must have elapsed since prior therapy that includes a monoclonal antibody

• Normal organ function

• All patients or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines

• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Exclusion Criteria:

• Patients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in girls who are postmenarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy and for 3 months after the last dose of GD2Bi-aATC; breastfeeding women should be excluded

• Patients who have an uncontrolled infection are not eligible

• Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible

Related Conditions & MeSH terms

• Disseminated Neuroblastoma
• Neuroblastoma
• Recurrent Neuroblastoma

Intervention

Biological:
• IL-2
Given SC
• GD2Bi-aATC
Given IV
• GM-CSF
Given SC

Other:
• laboratory evaluations of immune responses
Correlative studies

Locations

Country	Name	City	State
United States	University of Virginia, Department of Pediatrics, Hematology/Oncology	Charlottesville	Virginia
United States	Children's Hospital of Michigan	Detroit	Michigan
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
University of Virginia	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of GD2Bi-aATC	Safety of GD2Bi-aATC infusions is evaluated to determine MTD	35 days
Secondary	Anti-tumor activity	Objective response rate to GD2Bi-aATC infusions	Up to 12 months
Secondary	Immune responses after GD2Bi-aATC infusions	In vitro anti-tumor activity of patients' lymphocytes; changes in cytokine profile; changes in lymphocyte phenotypes	Up to 12 months